Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen)

Diabetes and Metabolism

Volumn 31, Issue 5, 2005, Pages 479-485

  Prevost G ^a   Phan, T M ^b   Mounier Vehier, C ^a   Fontaine, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b SANOFI   (France)

Author keywords

Guidelines; Hypertension; Risk factors; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; STATIN;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONSULTATION; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; FEMALE; FRANCE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFORMATION PROCESSING; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION;

EID: 27844456782     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70219-7     Document Type: Article

References (33)

1. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: Causes and death rates. Diabetologia 1990;33: 538-41
2. Epstein M. Diabetes and hypertension: the bad companions. J Hypertens Suppl 1997;15:S55-62
3. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 1998;316:823-8
4. UKPDS Study Group UKPDS 38 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13
5. UK Prospective Diabetes Study (UKPDS) Group (UKPDS 33). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
6. UK Prospective Diabetes Study Group UKPDS 39. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:713-20
7. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7
8. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20
9. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102: 1893-1900
10. Heart Protection Study Collaborative Group. Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
11. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46
12. American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care 2001;24 (Suppl 1):S1-133
13. Agence Nationale d'Accréditation et d'Évaluation en Santé. Stratégie de prise en charge du patient diabétique de type 2 à l'exclusion de la prise en charge des complications. Paris: ANAES;1999
14. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-23
15. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med. 2002;112:603-9
16. Miller CD, Phillips LS, Tate MK, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000; 23:444-8
17. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;2:754-8
18. George PB, Tobin KJ, Corpus RA, Devlin WH, O'Neill WW. Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines? Am Heart J. 2001;142:857-63
19. ANAES, Prise en charge des patients adultes atteints d'hypertension artérielle essentielle. Recommendations cliniques et données économiques, Paris: 2000
20. Mounier-Vehier C, Amah G, Duquenoy S, Fontaine P, Phan TM Is assessment of kidney involvement in patients with essential hypertension satisfactory? General medical observation results in a national study (PHENOMEN)] Arch Mal Coeur Vaiss 2003;96:792-75
21. ANAES, Modalités de dépistage et diagnostic biologique des dyslipidémies en prévention primaire. Paris: ANAES; 1999
22. Le Floch JP, Thervet F, Desriac I, Boyer JF, Simon D. Management of diabetic patients by general practitioners in France 1997: an epidemiological study. Diabetes Metab 2000;26:43-9
23. Julius S, Majahalme S, Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am J hypertens 2001;14:310-6
24. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309-17
25. Detournay B, Cros S, Charbonnel B, et al. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab 2000;26:363-9
26. Brown MJ, Castaigne A, de Leeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000;35:1038-42
27. Chamontin B, Poggi L, Lang T, et al. Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994, Am J Hypertens 1998; 11:759-62
28. Chamontin B, Lang T, Vaisse B, et al. Regional management of arterial hypertension in France. Report of a survey of general practioners, Arch Mal Coeur 2001;94:823-7
29. Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, Alexander CM. Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care 2004;27:694-8
30. Monnier L, Grimaldi A, Charbonnel B, et al. Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory. Diabetes Metab 2004;30:35-42
31. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001
32. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6
33. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003;26:355-9